Integra LifeSciences Holdings Corp. Given Consensus Recommendation of “Hold” by Brokerages (NASDAQ:IART)
Integra LifeSciences Holdings Corp. (NASDAQ:IART) has earned an average recommendation of “Hold” from the thirteen brokerages that are presently covering the company, American Banking News.com reports. Seven analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $48.09.
Integra LifeSciences Holdings Corp. (NASDAQ:IART) traded up 0.02% on Thursday, hitting $45.74. 15,763 shares of the company’s stock traded hands. Integra LifeSciences Holdings Corp. has a one year low of $33.13 and a one year high of $49.99. The stock has a 50-day moving average of $46.35 and a 200-day moving average of $46.07. The company’s market cap is $1.483 billion.
Integra LifeSciences Holdings Corp. (NASDAQ:IART) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.78 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.81 by $0.03. The company had revenue of $220.80 million for the quarter, compared to the consensus estimate of $223.37 million. On average, analysts predict that Integra LifeSciences Holdings Corp. will post $3.09 earnings per share for the current fiscal year.
IART has been the subject of a number of recent research reports. Analysts at Lake Street Capital initiated coverage on shares of Integra LifeSciences Holdings Corp. in a research note on Wednesday. They set a “buy” rating and a $55.00 price target on the stock. Analysts at Piper Jaffray raised their price target on shares of Integra LifeSciences Holdings Corp. from $57.00 to $59.00 in a research note on Thursday, February 27th.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) is an integrated medical technology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.